Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugging "undruggable" genes for cancer treatment: Are we making progress?

International journal of cancer - 1 Jan 2021

Duffy Michael J, Crown John

Abstract excerpt

RAS, TP53 (p53) and MYC are among the most frequently altered driver genes in cancer. Thus, RAS is the most frequently mutated oncogene, MYC the most frequently amplified gene and TP53 the most frequently mutated tumor suppressor gene and overall the most frequently mutated gene in cancer. Theoretically, therefore, these genes are highly attractive targets for cancer treatment. However, as the protein products of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinogenesis
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Hydrophobic and Hydrophilic Interactions

Share to Proto-Oncogene Proteins c-myc

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 32638380
DOI: 10.1002/ijc.33197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugging "undruggable" genes for cancer treatment: Are we making progress?PMID 32638380Read ↗

Targeting p53 for the treatment of cancerSemantic proximity Read ↗

Awakening guardian angels: drugging the p53 pathway.Semantic proximity Read ↗

TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors.Semantic proximity Read ↗

Drugging the p53 pathway: understanding the route to clinical efficacySemantic proximity Read ↗

The p53/MDM2/MDMX-targeted therapies—a clinical synopsisSemantic proximity Read ↗

Mutant p53 as a target for cancer treatment.Semantic proximity Read ↗

The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics UniverseSemantic proximity Read ↗

Falling out of the fold: tumorigenic mutations and p53.Semantic proximity Read ↗

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic AgentsSemantic proximity Read ↗

Therapeutic potential of targeting haploinsufficient genes in cancer.Semantic proximity Read ↗

p53 and MYC-regulated squalene epoxidase as Achilles heel in colorectal cancer.Semantic proximity Read ↗

Reactivating hope for TP53-mutated acute myeloid leukaemia?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.